Jon P. Stonehouse - 27 Feb 2026 Form 4 Insider Report for BIOCRYST PHARMACEUTICALS INC (BCRX)

Role
Director
Signature
/s/ Alane P. Barnes, by power of attorney
Issuer symbol
BCRX
Transactions as of
27 Feb 2026
Net transactions value
-$1,654,809
Form type
4
Filing time
03 Mar 2026, 16:34:13 UTC
Previous filing
23 Dec 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Stonehouse Jon P Director 4505 EMPEROR BLVD., SUITE 200, DURHAM /s/ Alane P. Barnes, by power of attorney 03 Mar 2026 0001385496

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction BCRX Common Stock Award $3,684 +421 +0.03% $8.75 1,323,850 27 Feb 2026 Direct F1
transaction BCRX Common Stock Options Exercise $985,304 +305,995 +23% $3.22 1,629,845 02 Mar 2026 Direct F2
transaction BCRX Common Stock Disposed to Issuer $2,643,797 -305,995 -19% $8.64 1,323,850 02 Mar 2026 Direct F2, F3
holding BCRX Common Stock 40,000 27 Feb 2026 By wife as co-trustee of the Caroline Stonehouse Irrevocable Trust
holding BCRX Common Stock 40,000 27 Feb 2026 By wife as co-trustee of the Samuel Stonehouse Irrevocable Trust

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction BCRX Emp. Stock Option (Right to Buy) Options Exercise $0 -305,995 -100% $0.000000 0 02 Mar 2026 Common Stock 305,995 $3.22 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 Shares of Common Stock issued to the reporting person in lieu of 50% of the prorated quarterly cash Board Member retainer of $7,375.
F2 This transaction was made pursuant to a plan adopted by the reporting person on November 28, 2022, as modified on May 13, 2024 and further modified on May 29, 2024, in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. The options were originally granted to the reporting person on May 23, 2016 and would have expired on May 23, 2026. The transaction occurred automatically and does not represent a discretionary transaction by the reporting person.
F3 The price in column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $8.54 to $8.81. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote.